Zhittya Logo.jpg
Zhittya Genesis Medicine announces: Free Zoom Webinar: Parkinson’s Disease Sufferers Motor Skills Improve by 50% After Medical Research Study
21 juin 2022 10h00 HE | Zhittya Genesis Medicine Inc
LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time...
Zhittya Logo.jpg
Zhittya Genesis Medicine Announces: Parkinson’s Disease Sufferers Motor Skills Improved by 50% After Medical Research Study
16 juin 2022 14h00 HE | Zhittya Genesis Medicine Inc
LAS VEGAS, June 16, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that the human test subjects in its first-in-human research study for the...
Vantage Market Research.png
Global Autologous Cell Therapy Product Market ($ 34.8 Bn by 2028) Growth Forecast at 17.1% CAGR During 2022 to 2028 COVID-19 Impact and Global Analysis by Vantage Market Research
04 mars 2022 03h40 HE | Vantage Market Research
WASHINGTON, March 04, 2022 (GLOBE NEWSWIRE) -- Recently, the Autologous Cell Therapy Product Market is changing the face of the medicinal treatment and therapeutics. The major factors driving the...
Sunshine Biopharma Logo
Sunshine Biopharma Expands Board of Directors
03 nov. 2021 12h35 HE | Sunshine Biopharma Inc.
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Sunshine Biopharma Logo
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
06 oct. 2021 08h00 HE | Sunshine Biopharma Inc.
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
SPNGNX_logo_hrz.jpg
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
07 juin 2021 07h00 HE | Spinogenix, Inc.
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board
20 avr. 2021 11h31 HE | Cognition Therapeutics, Inc.
Pittsburgh, April 20, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology
10 févr. 2021 08h00 HE | Cognition Therapeutics, Inc.
Pittsburgh, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology
01 févr. 2021 08h00 HE | Cognition Therapeutics, Inc.
PITTSBURGH, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Emergen logo.png
Intelligent Drug Discovery Market Size To Be Worth USD 3,711.8 Million by 2027 | Emergen Research
09 déc. 2020 13h00 HE | Emergen Research
Vancouver, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- The Global Intelligent Drug Discovery Market is forecast to be worth USD 3,711.8 Million by 2027, according to a current analysis by...